MSLN and neoplasm: For proof-of-concept we analyzed dose-dependent T-cell-mediated cytotoxicity on mesothelin (MSLN)-positive tumor cell lines NCIH596 (approx. 80,000 MSLN ABS/cell) and AsPC1 (approx. 50,000 MSLN ABS/cell) mediated by an analogous Prot-MSLN-TCB.